|
1
|
Attwa MH and El-Etreby SA: Guide for
diagnosis and treatment of hepatocellular carcinoma. World J
Hepatol. 7:1632–1651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group, : Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakajima T, Yasui K, Zen K, Inagaki Y,
Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, et al:
Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol
Res. 38:886–895. 2008.PubMed/NCBI
|
|
5
|
Pagliarini V, Giglio P, Bernardoni P, De
Zio D, Fimia GM, Piacentini M and Corazzari M: Downregulation of
E2F1 during ER stress is required to induce apoptosis. J Cell Sci.
128:1166–1179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rajendran P, Li F, Shanmugam MK, Kannaiyan
R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al:
Celastrol suppresses growth and induces apoptosis of human
hepatocellular carcinoma through the modulation of STAT3/JAK2
signaling cascade in vitro and in vivo. Cancer Prev Res. 5:631–643.
2012. View Article : Google Scholar
|
|
7
|
Feng L, Zhang D, Fan C, Ma C, Yang W, Meng
Y, Wu W, Guan S, Jiang B, Yang M, et al: ER stress-mediated
apoptosis induced by celastrol in cancer cells and important role
of glycogen synthase kinase-3β in the signal network. Cell Death
Dis. 4:e7152013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fribley AM, Miller JR, Brownell AL,
Garshott DM, Zeng Q, Reist TE, Narula N, Cai P, Xi Y, Callaghan MU,
et al: Celastrol induces unfolded protein response-dependent cell
death in head and neck cancer. Exp Cell Res. 330:412–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ,
Liu YQ, Pu JX, Xiao WL, Sun HD, et al: Overexpression and small
molecule-triggered downregulation of CIP2A in lung cancer. PLoS
One. 6:e201592011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Z, Ma L, Wen ZS, Cheng YX and Zhou GB:
Ethoxysanguinarine induces inhibitory effects and downregulates
CIP2A in lung cancer cells. ACS Med Chem Lett. 5:113–118. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu JL, Zeng GZ, Liu XL, Liu YQ, Hu ZG,
Liu Y, Tan NH and Zhou GB: Small compound bigelovin exerts
inhibitory effects and triggers proteolysis of E2F1 in multiple
myeloma cells. Cancer Sci. 104:1697–1704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diefenbach J and Bürkle A: Introduction to
poly(ADP-ribose) metabolism. Cell Mol Life Sci. 62:721–730. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET
and Yu Q: Inhibitors of histone deacetylases target the Rb-E2F1
pathway for apoptosis induction through activation of pro-apoptotic
protein Bim. Proc Natl Acad Sci USA. 102:pp. 16090–16095. 2005;
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsumura I, Tanaka H and Kanakura Y: E2F1
and c-Myc in cell growth and death. Cell Cycle. 2:333–338. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lam SK, Li YY, Zheng CY, Leung LL and Ho
JC: E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Int J Oncol. 45:2033–2043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawate S, Fukusato T, Ohwada S, Watanuki A
and Morishita Y: Amplification of c-myc in hepatocellular
carcinoma: Correlation with clinicopathologic features,
proliferative activity and p53 overexpression. Oncology.
57:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ciechanover A: Proteolysis: From the
lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol.
6:79–87. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Adams J: The proteasome: A suitable
antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huynh H: Molecularly targeted therapy in
hepatocellular carcinoma. Biochem Pharmacol. 80:550–560. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Newman DJ and Giddings LA: Natural
products as leads to antitumor drugs. Phytochem Rev. 13:123–137.
2014. View Article : Google Scholar
|
|
22
|
Liu Z, Ma L and Zhou GB: The main
anticancer bullets of the Chinese medicinal herb, thunder god vine.
Molecules. 16:5283–5297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li PP, He W, Yuan PF, Song SS, Lu JT and
Wei W: Celastrol induces mitochondria-mediated apoptosis in
hepatocellular carcinoma Bel-7402 cells. Am J Chin Med. 43:137–148.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan YY, Guo Y, Zhang W, Ma CG, Zhang YX,
Wang C and Wang HX: Celastrol enhanced the anticancer effect of
lapatinib in human hepatocellular carcinoma cells in vitro. J BUON.
19:412–418. 2014.PubMed/NCBI
|
|
25
|
Nicholson DW: Caspase structure,
proteolytic substrates, and function during apoptotic cell death.
Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelmann D, Knoll S, Ewerth D, Steder M,
Stoll A and Pützer BM: Functional interplay between E2F1 and
chemotherapeutic drugs defines immediate E2F1 target genes crucial
for cancer cell death. Cell Mol Life Sci. 67:931–948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Conner EA, Lemmer ER, Omori M, Wirth PJ,
Factor VM and Thorgeirsson SS: Dual functions of E2F-1 in a
transgenic mouse model of liver carcinogenesis. Oncogene.
19:5054–5062. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rabbani F, Richon VM, Orlow I, Lu ML,
Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G and Cordon-Cardo
C: Prognostic significance of transcription factor E2F-1 in bladder
cancer: Genotypic and phenotypic characterization. J Natl Cancer
Inst. 91:874–881. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zacharatos P, Kotsinas A, Evangelou K,
Karakaidos P, Vassiliou LV, Rezaei N, Kyroudi A, Kittas C,
Patsouris E, Papavassiliou AG, et al: Distinct expression patterns
of the transcription factor E2F-1 in relation to tumour growth
parameters in common human carcinomas. J Pathol. 203:744–753. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Engelmann D and Pützer BM: The dark side
of E2F1: In transit beyond apoptosis. Cancer Res. 72:571–575. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu LC, Wen ZS, Qiu YT, Chen XQ, Chen HB,
Wei MM, Liu Z, Jiang S and Zhou GB: Largazole arrests cell cycle at
G1 phase and triggers proteasomal degradation of E2F1 in lung
cancer cells. ACS Med Chem Lett. 4:921–926. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gorgoulis VG, Zacharatos P, Mariatos G,
Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N,
Kittas C and Papavassiliou AG: Transcription factor E2F-1 acts as a
growth-promoting factor and is associated with adverse prognosis in
non-small cell lung carcinomas. J Pathol. 198:142–156. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eymin B, Gazzeri S, Brambilla C and
Brambilla E: Distinct pattern of E2F1 expression in human lung
tumours: E2F1 is upregulated in small cell lung carcinoma.
Oncogene. 20:1678–1687. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim
YD and Kim HY: E2F1 expression is related with the poor survival of
lymph node-positive breast cancer patients treated with
fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res
Treat. 82:11–16. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu H, Yang W, He LJ, Ding WJ, Zheng L,
Liao SD, Huang P, Lu W, He QJ and Yang B: Upregulating Noxa by ER
stress, celastrol exerts synergistic anti-cancer activity in
combination with ABT-737 in human hepatocellular carcinoma cells.
PLoS One. 7:e523332012. View Article : Google Scholar : PubMed/NCBI
|
